Delivery of solely small RNA molecules for the upregulation of endogenous VEGF-A is a new and promising gene therapy approach for the treatment of MI and offers also a potential new strategy for the regulation of other endogenous therapeutic genes. Here, VEGFA is linked to myocardial infarction.